SLXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Silexion Therapeutics Corp (SLXN) is not a good buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, financial performance is weak, and there are no strong positive catalysts or trading signals to support an immediate investment decision.
The technical indicators for SLXN are bearish. The MACD is below zero and negatively contracting, RSI is neutral at 31.846, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.729, with key support at 1.546 and resistance at 1.913.
The company is targeting unmet needs in KRAS-driven cancers with a unique siRNA platform and is positioned to enter late-stage clinical development. Regulatory submissions are planned in Q4 and Q1 for Israel and Europe, respectively. An analyst has initiated coverage with a Buy rating and a $6 price target.
No recent news. Hedge funds and insiders show neutral sentiment with no significant trading trends. Stock trend analysis predicts a 30% chance of further declines in the short term (-0.46% next day, -2.97% next week, -1.78% next month).
The company's Q3 2025 financials are weak. Revenue remains at 0 with no growth, net income dropped significantly by -72.50% YoY to -$3,262,000, and EPS fell sharply by -97.99% YoY to -2.88. Gross margin remains at 0 with no improvement.
Litchfield Hills analyst Theodore O'Neill initiated coverage with a Buy rating and a $6 price target, citing the company's innovative approach to KRAS-driven cancer treatment and upcoming regulatory submissions. However, no other analyst ratings or updates are available.
